Biography
Sam co-founded miR Scientific in 2014. Sam is a serial entrepreneur and a renowned executive who throughout his career held senior executive and board level positions developing game-changing technologies and companies across industries, including Biotech (president – Errant Gene Therapeutics), Art Authentication (CEO – Provenire Authentication), Aquaculture (Chairman – Greenfins Global) and Financial Services (Mission Markets Inc., a pioneering financial services firm focused on impact and sustainability markets.). Sam attended the American University of Paris in France and Macalester College in St. Paul, MN. He is a member of the Board of Trustees and Board of Selectors of the Jefferson Awards for Public Service.

Liquid Biopsy Showcase Showcase:

miR Scientific (www.mirscientific.com) is a precision bioscience company that has developed proprietary, non-invasive liquid biopsy urine tests that definitively detect, accurately score and continuously monitor prostate and bladder cancers.

miR Scientific Sentinel™️ PCa and CS Tests, Revolutionizing the Standard of Care Supporting Urologic Oncology
In the face of debilitating global prevalence and disease burden of urological cancer, miR has developed a urological oncology disease management platform that is centered around it’s proprietary non-invasive liquid biopsy urine tests. Based on profiling sncRNA isolated from Urinary Exosomes, the tests detect, score and continuously monitor prostate and bladder cancers with industry-leading accuracy. The presentation will show how the validated platform will comprehensively transform patient health outcomes and optimize the cost and availability of health service utilization.